Literature DB >> 26165584

γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria.

Estela Noguera-Ortega1, Rosa Maria Rabanal2, Silvia Secanella-Fandos1, Eduard Torrents3, Marina Luquin1, Esther Julián4.   

Abstract

PURPOSE: γ Irradiated Mycobacterium bovis bacillus Calmette-Guérin has shown in vitro and ex vivo antitumor activity. However, to our knowledge the potential antitumor capacity has not been demonstrated in vivo. We studied the in vivo potential of γ irradiated bacillus Calmette-Guérin and γ irradiated M. brumae, a saprophytic mycobacterium that was recently described as an immunotherapeutic agent.
MATERIALS AND METHODS: The antitumor capacity of γ irradiated M. brumae was first investigated by analyzing the in vitro inhibition of bladder tumor cell proliferation and the ex vivo cytotoxic effect of M. brumae activated peripheral blood cells. The effect of γ irradiated M. brumae or bacillus Calmette-Guérin intravesical treatment was then compared to treatment with live mycobacteria in the orthotopic murine model of bladder cancer.
RESULTS: Nonviable M. brumae showed a capacity to inhibit in vitro bladder cancer cell lines similar to that of live mycobacteria. However, its capacity to induce cytokine production was decreased compared to that of live M. brumae. γ Irradiated M. brumae could activate immune cells to inhibit tumor cell growth, although to a lesser extent than live mycobacteria. Finally, intravesical treatment with γ irradiated M. brumae or bacillus Calmette-Guérin significantly increased survival with respect to that of nontreated tumor bearing mice. Both γ irradiated mycobacteria showed lower survival rates than those of live mycobacteria but the minor efficacy of γ irradiated vs live mycobacteria was only significant for bacillus Calmette-Guérin.
CONCLUSIONS: Our results show that although γ irradiated mycobacteria is less efficacious than live mycobacteria, it induces an antitumor effect in vivo, avoiding the possibility of further mycobacterial infections.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BCG vaccine; Mycobacterium; gamma rays; immunotherapy; urinary bladder neoplasms

Mesh:

Substances:

Year:  2015        PMID: 26165584     DOI: 10.1016/j.juro.2015.07.011

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update.

Authors:  Sandra Guallar-Garrido; Esther Julián
Journal:  Immunotargets Ther       Date:  2020-02-13

2.  Draft Genome Sequence of Mycobacterium brumae ATCC 51384.

Authors:  Giuseppe D'Auria; Eduard Torrents; Marina Luquin; Iñaki Comas; Esther Julián
Journal:  Genome Announc       Date:  2016-04-28

3.  Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment.

Authors:  Estela Noguera-Ortega; Núria Blanco-Cabra; Rosa Maria Rabanal; Alejandro Sánchez-Chardi; Mónica Roldán; Sandra Guallar-Garrido; Eduard Torrents; Marina Luquin; Esther Julián
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

Review 4.  Managing the adverse events of intravesical bacillus Calmette-Guérin therapy.

Authors:  Karel Decaestecker; Willem Oosterlinck
Journal:  Res Rep Urol       Date:  2015-10-23

5.  Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice.

Authors:  Estela Noguera-Ortega; Rosa M Rabanal; Elisabet Gómez-Mora; Cecilia Cabrera; Marina Luquin; Esther Julián
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.